NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00471497,A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP),https://clinicaltrials.gov/study/NCT00471497,ENESTnd,COMPLETED,"In this study, the efficacy and safety of two nilotinib doses, 300 mg twice daily and 400 mg twice daily, were compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).

An extension protocol was included in this study design to allow patients who did not show sufficient response to their assigned treatments the opportunity to receive imatinib 400 mg BID (option available until protocol amendment 7) or nilotinib 400 mg BID, using an abbreviated safety and efficacy assessment schedule.",YES,"Myelogenous Leukemia, Chronic",DRUG: nilotinib|DRUG: imatinib,"Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation, MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months., Baseline, 12 months|Percentage of Participants With MMR at 12 Months Between All 3 Arms by Sokal Risk Group With Imputation, MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months., 12 months","Rates of Durable MMR at 24 Months Between All 3 Arms, Durable MMR at 24 months is defined as having MMR both at 12 months and at 24 months, and with no documented loss of MMR between these 12 month and 24 month time points., 24 months|Rate of Complete Cytogenetic Response (CCyR) in Nilotinib Treatment Arms With Imatinib at 12 Months and Beyond 12 Months, CCyR is defined as 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics. Patients with no CCyR as the best response by any specific time point, all missing cytogenetic evaluations by that time point or Ph- at baseline are combined as ""Nocomplete cytogenetic response""., 12, 24, 36, 48, 60, 72 months (M)|Rate of Major Molecular Response (MMR) at 12 Months Between Two Nilotinib Arms, MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months based on 12-month cut-off interim data., 12 months|Rate of MMR at 6 Months and Beyond in All 3 Treatment Arms, MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 6 months and beyond up to 120 months based on final data., 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months|Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib, Molecular response of \<=0.01% is defined as BCR-ABL ratio (%) on IS \<= 0.01% (corresponds to \>=4 log reduction of BCR-ABL transcripts from standardized baseline value), at 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months|Rate of a ≥ 4.5 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib, This is the molecular response of \<=0.0032% is defined as BCR-ABL ratio (%) on IS \<= 0.0032% (corresponds to \>=4.5 log reduction of BCR-ABL transcripts from standardized baseline value), at 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months|Time to First MMR, Time to MMR is defined as time from date of randomization to the date of the first documented MMR in nilotinib treatment arms, compared to imatinib in adult patients with Ph+ CML in CP., up to 84 months|Duration of MMR, Duration of MMR for patients with MMR is defined as the time between date of MMR and the earliest of the following: loss of MMR, CML-related death or progression to AP/BC during study treatment The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported., approx. 11 years|Time to Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts, Time to BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% is defined as: date of first BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% - date of randomization +1., up to 84 months|Duration of Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts, It is defined as the time from the date of first documented BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% to the earliest of the following: Loss of BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032%, respectively, CML-related death or progression to AP/BC during study treatment. The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported., approx. 11 years|Rate of Hematologic Response, Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver)., 12 months, 24 months, Overall on Core study (approx. 11 years)|Time to Complete Cytogenic Response (CCyR), Time to CCyR is defined as the time from the date of randomization to the date of first documented CCyR, 24 months|Duration of CCyR, Duration of CCyR is defined as the time from date of first documented CCyR to the earliest date of loss of CCyR., up to 72 months|Progression-free Survival (PFS), Progression-free survival is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of death from any cause occurring in the core or extension study, or during the follow-up period after discontinuation of core or extension study, approx. 11 years|Event-free Survival (EFS), Event-free survival is defined as the time from the date of randomization to the date of first occurrence of any of the following: death due to any cause (if death is the primary reason for discontinuation), progression to AP or BC, loss of PCyR, loss of CCyR, loss of CHR, approx. 11 years|Overall Survival (OS), OS is defined as the time from the date of randomization to the date death. Up to 10 calendar years of follow up from the date when the last patient randomized received the first dose of study drug in all active treatment arms of adult patients with Ph+ CML CP., approx. 11 years|Actual Dose-intensity, Actual dose intensity is defined as total dose over time on treatment, approx. 11 years|Time to Progression to AP/BC, Time to progression to AP/BC is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of CML related death., approx. 11 years|Pharmacokinetics: Cmax, Cmax is defined as the maximum serum concentration after dose, any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration|Pharmacokinetics: Cmin, Cmin is defined as the minimum serum concentration after dose, any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration|Pharmacokinetics: Tmax, Tmax is defined as the sampling time when maximum measured serum concentration occurs, any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration|Pharmacokinetics: AUC0-last, AUC0-last is defined as area under concentration-time curve from time zero to the last measurable sample, calculated by log-linear trapezoidal method, any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration|Rate of Hematologic Response on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension), Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver)., Overall for Extension study for approx. 10 years|Rate of Complete Cytogenetic Response (CCyR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension), Rate of CCyR is defined as the percentage of participants in complete cytogenetic response (CCyR). CcyR is defined as 0% of Ph+ metaphases in the bone marrow., Overall for Extension study for approx. 10 years|Rate of Major Molecular Response (MMR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension), Rate of MMR is defined as the percentage pf participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)), Overall for Extension study for approx. 10 years|Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension), Molecular response of \<=0.01% is defined as BCR-ABL ratio (%) on IS \<= 0.01% (corresponds to \>=4 log reduction of BCR-ABL transcripts from standardized baseline value), Overall for Extension study for approx. 10 years|Rate of ≥ 4.5 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension), Molecular response of \<=0.0032% is defined as BCR-ABL ratio (%) on IS \<= 0.0032% (corresponds to \>=4.5 log reduction of BCR-ABL transcripts from standardized baseline value), Overall for Extension study for approx. 10 years|Presence of Newly Observed BCR-ABL Mutations in Patients Post-baseline and Correlate With Response to Treatment With Imatinib and Nilotinib (Extension), This is the percentage of patients with any emergent mutation on extension treatment. The mutation comprised of T315T, less sensitive to nilotinib, unknown and sensitive to nilotinib., Overall for Extension study for approx. 10 years",,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,846,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,CAMN107A2303|2007-000208-34,2007-07-31,2009-09-02,2019-08-21,2007-05-10,2013-06-17,2020-11-18,"University of California at Los Angeles Dept. of Hematology Clinic, Los Angeles, California, 90095, United States|Kaiser Permanente - California Southern Dept of Kaiser South 3, San Diego, California, 92120, United States|Kaiser Permanente - California Northern Vallejo Med Center/Med Offices, Vallejo, California, 94589, United States|Kaiser Permanente - California Northern Kaiser Med, Vallejo, California, 94609, United States|Rocky Mountain Cancer Centers RMCC - Colorado Springs, Greenwood Village, Colorado, United States|Florida Cancer Specialists Dept. FloridaCancerSpecialists, Fort Myers, Florida, 33901, United States|Advanced Medical Specialties Research Dept., Miami, Florida, 33176, United States|Cancer Centers of Florida PA Cancer Centers of FL, Ocoee, Florida, 34761, United States|Florida Retina Institute Flordia Cancer Affilates, Orlando, Florida, 32804, United States|University of Chicago Section of Hematology/Oncology, Chicago, Illinois, 60637, United States|Indiana Blood and Marrow Institute Dept. of Indiana Blood&Marrow, Beech Grove, Indiana, 46107, United States|University of Iowa Hospitals and Clinics Dept.of U of Iowa Hosp&Clinics, Iowa City, Iowa, 52242, United States|Kansas City Cancer Center KCCC Business Office, Overland Park, Kansas, 66210, United States|LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center, New Orleans, Louisiana, 70115, United States|Michigan State University / Breslin Cancer Center Breslin Cancer Center, Lansing, Michigan, 48824, United States|Missouri Cancer Associates Dept. of Boone Hospital Center, Columbia, Missouri, 65201, United States|Hematology Oncology Consultants, Inc. Deptof Hem. Onc.Consunsultants, Saint Louis, Missouri, 63136, United States|Hackensack University Medical Center Department of Research, Hackensack, New Jersey, 07601, United States|Memorial Sloan Kettering Cancer Center Clinical Trials Office, New York, New York, 10021, United States|University of North Carolina UNC Lineberger Cancer Center, Chapel Hill, North Carolina, 27514, United States|Wake Forest University Health Sciences Dept. of Industry Research, Winston-Salem, North Carolina, 27157, United States|University of Cincinnati / Barrett Cancer Center Dept.of Internal Med., Cincinnati, Ohio, 45219, United States|Cleveland Clinic Foundation CCF, Cleveland, Ohio, 44195, United States|Northwest Cancer Specialists Compass Oncology -BKM, Portland, Oregon, 97210, United States|Cancer Centers of the Carolinas CC of C -Eastside, Greenville, South Carolina, 29605, United States|Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology, Chattanooga, Tennessee, 37404, United States|Tennessee Oncology Dept. of Centennial Medical, Nashville, Tennessee, 37203, United States|Texas Cancer Center ( Medical City Dallas Hospital), Dallas, Texas, 75230, United States|Cancer Care Centers of South Texas HOAST CCC of So.TX- Medical Center, San Antonio, Texas, 78229, United States|Tyler Cancer Center, Tyler, Texas, 75702, United States|Utah Cancer Specialists, Salt Lake City, Utah, 84106, United States|Novartis Investigative Site, Caba, Buenos Aires, C1221ADC, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, B1902AVG, Argentina|Novartis Investigative Site, Salzburg, 5020, Austria|Novartis Investigative Site, Wien, A-1090, Austria|Novartis Investigative Site, Bruxelles, 1000, Belgium|Novartis Investigative Site, Charleroi, 6000, Belgium|Novartis Investigative Site, Gent, 9000, Belgium|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Yvoir, 5530, Belgium|Novartis Investigative Site, Brasilia, DF, 70330-150, Brazil|Novartis Investigative Site, Curitiba, PR, 80060-900, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, 20211-030, Brazil|Novartis Investigative Site, Campinas, SP, 13083-970, Brazil|Novartis Investigative Site, Jau, SP, 17210-080, Brazil|Novartis Investigative Site, Sao Paulo, SP, 05403 000, Brazil|Novartis Investigative Site, São Paulo, SP, 01224-000, Brazil|Novartis Investigative Site, São Paulo, SP, 01401-901, Brazil|Novartis Investigative Site, Vancouver, British Columbia, V5Z 4E3, Canada|Novartis Investigative Site, Vancouver, British Columbia, V5Z 4E6, Canada|Novartis Investigative Site, Toronto, Ontario, M5G 2M9, Canada|Novartis Investigative Site, Quebec, G1J 1Z4, Canada|Novartis Investigative Site, Quebec, G1R 2J6, Canada|Novartis Investigative Site, Bogota, Cundinamarca, 110111, Colombia|Novartis Investigative Site, Bogota, 110001, Colombia|Novartis Investigative Site, Praha 2, Czech Republic, 128 20, Czechia|Novartis Investigative Site, Olomouc, CZE, 775 20, Czechia|Novartis Investigative Site, Copenhagen, DK-2100, Denmark|Novartis Investigative Site, Vejle, DK-7100, Denmark|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, HUS Helsinki, FIN-00029, Finland|Novartis Investigative Site, Turku, FIN-20521, Finland|Novartis Investigative Site, Paris Cedex 10, Cedex 10, 75475, France|Novartis Investigative Site, Caen, Cedex, 14033, France|Novartis Investigative Site, Saint Priest en Jarez, Loire, 42270, France|Novartis Investigative Site, Angers Cedex 1, 49033, France|Novartis Investigative Site, Bordeaux, 33076, France|Novartis Investigative Site, Creteil, 94010, France|Novartis Investigative Site, Grenoble, 38043, France|Novartis Investigative Site, Lille, 59037, France|Novartis Investigative Site, Marseille, 13273, France|Novartis Investigative Site, Nantes, 44035, France|Novartis Investigative Site, Nice Cedex, 06202, France|Novartis Investigative Site, Pierre Benite Cedex, 69495, France|Novartis Investigative Site, Poitiers, 86000, France|Novartis Investigative Site, Rennes, 35019, France|Novartis Investigative Site, Toulouse, 31059, France|Novartis Investigative Site, Vandoeuvre les Nancy, 54511, France|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, 68305, Germany|Novartis Investigative Site, Berlin, 13353, Germany|Novartis Investigative Site, Duesseldorf, 40225, Germany|Novartis Investigative Site, Eisenach, 99817, Germany|Novartis Investigative Site, Frankfurt, 60590, Germany|Novartis Investigative Site, Hamburg, 20246, Germany|Novartis Investigative Site, Kiel, 24105, Germany|Novartis Investigative Site, Koeln, 50937, Germany|Novartis Investigative Site, Leipzig, 04103, Germany|Novartis Investigative Site, Muenchen, 81675, Germany|Novartis Investigative Site, Ulm, 89081, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Budapest, 1097, Hungary|Novartis Investigative Site, Alessandria, AL, 15100, Italy|Novartis Investigative Site, Ancona, AN, 60126, Italy|Novartis Investigative Site, Bergamo, BG, 24127, Italy|Novartis Investigative Site, Bologna, BO, 40138, Italy|Novartis Investigative Site, Catania, CT, 95123, Italy|Novartis Investigative Site, Firenze, FI, 50134, Italy|Novartis Investigative Site, Genova, GE, 16132, Italy|Novartis Investigative Site, Milano, MI, 20162, Italy|Novartis Investigative Site, Pescara, PE, 65124, Italy|Novartis Investigative Site, Pisa, PI, 56126, Italy|Novartis Investigative Site, Pavia, PV, 27100, Italy|Novartis Investigative Site, Reggio Calabria, RC, 89124, Italy|Novartis Investigative Site, Roma, RM, 00133, Italy|Novartis Investigative Site, Roma, RM, 00144, Italy|Novartis Investigative Site, Roma, RM, 00161, Italy|Novartis Investigative Site, Siena, SI, 53100, Italy|Novartis Investigative Site, Udine, UD, 33100, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigative Site, Napoli, 80132, Italy|Novartis Investigative Site, Perugia, 06129, Italy|Novartis Investigative Site, Nagoya, Aichi, 453-8511, Japan|Novartis Investigative Site, Nagoya, Aichi, 466 8560, Japan|Novartis Investigative Site, Maebashi city, Gunma, 371 8511, Japan|Novartis Investigative Site, Maebashi, Gunma, 371-0821, Japan|Novartis Investigative Site, Sapporo city, Hokkaido, 060 8648, Japan|Novartis Investigative Site, Sapporo, Hokkaido, 003-0006, Japan|Novartis Investigative Site, Nishinomiya, Hyogo, 663 8501, Japan|Novartis Investigative Site, Tsukuba city, Ibaraki, 305-8576, Japan|Novartis Investigative Site, Kanazawa-city, Ishikawa, 920-8641, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, 860-8556, Japan|Novartis Investigative Site, Tsu-city, Mie, 514-8507, Japan|Novartis Investigative Site, Nagasaki-city, Nagasaki, 852-8501, Japan|Novartis Investigative Site, Osaka Sayama, Osaka, 589 8511, Japan|Novartis Investigative Site, Suita city, Osaka, 565 0871, Japan|Novartis Investigative Site, Hidaka-city, Saitama, 350-1298, Japan|Novartis Investigative Site, Hamamatsu-city, Shizuoka, 431-3192, Japan|Novartis Investigative Site, Shimotsuke, Tochigi, 329-0498, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, 113 8655, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8519, Japan|Novartis Investigative Site, Chuo ku, Tokyo, 104 0045, Japan|Novartis Investigative Site, Shinagawa ku, Tokyo, 141 8625, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160 8582, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160-0023, Japan|Novartis Investigative Site, Akita, 010-8543, Japan|Novartis Investigative Site, Chiba, 260 8677, Japan|Novartis Investigative Site, Hiroshima, 734-8551, Japan|Novartis Investigative Site, Niigata, 951 8520, Japan|Novartis Investigative Site, Osaka, 545-8586, Japan|Novartis Investigative Site, Saitama, 330 8503, Japan|Novartis Investigative Site, Seoul, Korea, 05505, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho Gu, 06591, Korea, Republic of|Novartis Investigative Site, Jeollanam-do, 519763, Korea, Republic of|Novartis Investigative Site, Seoul, 03080, Korea, Republic of|Novartis Investigative Site, Seoul, 06351, Korea, Republic of|Novartis Investigative Site, Taegu, 41944, Korea, Republic of|Novartis Investigative Site, Selangor, 68000, Malaysia|Novartis Investigative Site, Mexico, Distrito Federal, 06726, Mexico|Novartis Investigative Site, Monterrey, Nuevo Leon, 64460, Mexico|Novartis Investigative Site, Amsterdam, 1081 HV, Netherlands|Novartis Investigative Site, Oslo, NO-0310, Norway|Novartis Investigative Site, Trondheim, 7006, Norway|Novartis Investigative Site, Katowice, 40032, Poland|Novartis Investigative Site, Lublin, 20-081, Poland|Novartis Investigative Site, Rzeszow, 35 055, Poland|Novartis Investigative Site, Warszawa, 02-097, Poland|Novartis Investigative Site, Wroclaw, 50-367, Poland|Novartis Investigative Site, Moscow, 125167, Russian Federation|Novartis Investigative Site, Novosibirsk, 630051, Russian Federation|Novartis Investigative Site, Saint Petersburg, 197022, Russian Federation|Novartis Investigative Site, Singapore, 119228, Singapore|Novartis Investigative Site, Singapore, 169608, Singapore|Novartis Investigative Site, Bratislava, Slovak Republic, 833 10, Slovakia|Novartis Investigative Site, Bratislava, 85107, Slovakia|Novartis Investigative Site, Bloemfontein, 9301, South Africa|Novartis Investigative Site, Cape Town, 7925, South Africa|Novartis Investigative Site, Parktown, 2193, South Africa|Novartis Investigative Site, Pretoria, 0001, South Africa|Novartis Investigative Site, Pretoria, 0027, South Africa|Novartis Investigative Site, Elche, Alicante, 03203, Spain|Novartis Investigative Site, Granada, Andalucia, 18014, Spain|Novartis Investigative Site, Malaga, Andalucia, 29010, Spain|Novartis Investigative Site, Santander, Cantabria, 39008, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, 37007, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08036, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, 08907, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46010, Spain|Novartis Investigative Site, La Coruna, Galicia, 15006, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, 15706, Spain|Novartis Investigative Site, Bilbao, Pais Vasco, 48013, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, 20080, Spain|Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife, 38320, Spain|Novartis Investigative Site, Madrid, 28006, Spain|Novartis Investigative Site, Madrid, 28034, Spain|Novartis Investigative Site, Madrid, 28046, Spain|Novartis Investigative Site, Zaragoza, 50009, Spain|Novartis Investigative Site, Göteborg, SE-413 45, Sweden|Novartis Investigative Site, Huddinge, SE-14186, Sweden|Novartis Investigative Site, Lulea, SE 971 80, Sweden|Novartis Investigative Site, Lund, SE-221 85, Sweden|Novartis Investigative Site, Orebro, SE-701 85, Sweden|Novartis Investigative Site, Stockholm, SE-171 76, Sweden|Novartis Investigative Site, Sundsvall, SE-851 86, Sweden|Novartis Investigative Site, Umeå, SE-901 85, Sweden|Novartis Investigative Site, Uppsala, SE-751 85, Sweden|Novartis Investigative Site, Geneve, 1205, Switzerland|Novartis Investigative Site, Kaohsiung City, 83301, Taiwan|Novartis Investigative Site, Taipei, 10002, Taiwan|Novartis Investigative Site, Taoyuan, 33305, Taiwan|Novartis Investigative Site, Bangkok, 10330, Thailand|Novartis Investigative Site, Bangkok, 10400, Thailand|Novartis Investigative Site, Bangkok, 10700, Thailand|Novartis Investigative Site, Istanbul, TUR, 34098, Turkey|Novartis Investigative Site, Adana, 01330, Turkey|Novartis Investigative Site, Ankara, 06500, Turkey|Novartis Investigative Site, Izmir, 35340, Turkey|Novartis Investigative Site, Glasgow, G12 OYN, United Kingdom|Novartis Investigative Site, Leeds, LS9 7TF, United Kingdom|Novartis Investigative Site, Liverpool, L7 8XP, United Kingdom|Novartis Investigative Site, London, W12 0HS, United Kingdom|Novartis Investigative Site, Nottingham, NG5 1PB, United Kingdom|Novartis Investigative Site, Caracas, Distrito Capital, 1010, Venezuela",
